^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

320MO - A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC)

Published date:
09/05/2022
Excerpt:
With a median follow-up of 16 months (mo), the median overall survival (OS) was 7 mo in pts with liver mCRC, 14 mo in the overall population, and has exceeded 15 mo (not reached) in pts without liver disease. 5 pts remain on study without PD (12 – 19 mo since treatment start)....RIN has substantial activity in MSS mCRC patients without liver involvement with an iRECIST ORR of 36%, iDCR of 82%, and an iRECIST mPFS of 6 mo. Clinical benefits were seen irrespective of BRAF and RAS status.
Trial ID: